stockrowDianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
Follow DNTH
Alert me
Dianthus Therapeutics, Inc. (DNTH) Free cash flow
Dianthus Therapeutics, Inc.'s free cash flow for fiscal 2025 was −$129.3M, compared with −$78.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$175.9M. Over the past ten years it has ranged from −$129.3M (fiscal 2025) to −$6.7M (fiscal 2016) — the current reading is the lowest in ten years. Free cash flow has fallen for 3 consecutive fiscal years. Dianthus Therapeutics, Inc. ranks 525th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$129.3M | — |
| FY2024 | −$78.3M | — |
| FY2023 | −$37.0M | — |
| FY2022 | −$29.2M | — |
| FY2021 | −$60.8M | — |
| FY2020 | −$64.4M | — |
| FY2019 | −$60.2M | — |
| FY2018 | −$49.5M | — |
| FY2017 | −$24.5M | — |
| FY2016 | −$6.7M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$50.7M | — |
| Jun 2026 | −$49.2M | — |
| Mar 2026 | −$28.9M | — |
| Dec 2025 | −$47.1M | — |
| 35 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TVTX Travere Therapeutics, Inc. compare | $85.3M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$121.8M |
| MANE Veradermics Incorporated compare | −$123.0M |
| DFTX Definium Therapeutics, Inc. compare | −$168.0M |
| DNTH Dianthus Therapeutics, Inc. | −$175.9M |
| EWTX Edgewise Therapeutics, Inc. compare | −$202.3M |
| ERAS Erasca, Inc. compare | −$252.1M |
| COGT Cogent Biosciences, Inc. compare | −$309.2M |
| CRSP CRISPR Therapeutics AG compare | −$376.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on DNTH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement